RT Journal Article
SR Electronic
T1 Donor-Specific Antibody Testing is an Effective Surveillance Strategy for High-Risk Antibody Mediated Rejection in Heart Transplant Patients in the Contemporary Era
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.01.23299311
DO 10.1101/2023.12.01.23299311
A1 Cusi, Vincenzo
A1 Cardenas, Ashley
A1 Tada, Yuko
A1 Vaida, Florin
A1 Wettersten, Nicholas
A1 Chak, Jennifer
A1 Pretorius, Victor
A1 Urey, Marcus Anthony
A1 Morris, Gerald P.
A1 Lin, Grace
A1 Kim, Paul J.
YR 2024
UL http://medrxiv.org/content/early/2024/10/01/2023.12.01.23299311.abstract
AB Background: Pathologic antibody mediated rejection (pAMR) evaluation and donor specific antibody (DSA) testing are recommended in the first year after heart transplantation (HTx) in adult patients. Whether DSA testing adds prognostic information to contemporary pAMR surveillance has not been fully studied.Methods: This was a single center study of consecutive endomyocardial biopsies (EMB) performed between November 2010 and February 2023 in adult HTx patients. The primary objective was to evaluate whether DSA testing contributes additional information to pAMR surveillance to better predict overall survival. Secondary endpoints included cardiac allograft dysfunction and loss.Results: A total of 6,033 EMBs from 544 HTx patients were reviewed for the study. The pAMR+/DSA+ group had significantly lower overall survival versus the pAMR-/DSA-group (hazard ratio [HR] = 2.63; 95% confidence interval [CI], 1.35-5.11; pc = 0.013). In the pAMR+/DSA+ group, patients with cardiac allograft dysfunction, compared to those without allograft dysfunction, had significantly lower overall and cardiac survival (pc < 0.001 for both). In contrast, pAMR+/DSA+ and pAMR-/DSA-patients without cardiac allograft dysfunction showed no difference in overall and cardiac survival. Primary graft dysfunction (PGD) was a novel risk factor for development of de novo DSAs (dnDSA) three weeks post-HTx (p = 0.007).Conclusions: DSA testing as the primary surveillance method can identify high-risk pAMR+/DSA+ patients. Surveillance pAMR testing in the contemporary era may need to be reevaluated. Earlier DSA testing at 10-14 days post-HTx should be considered in PGD patients.Competing Interest StatementPJK reports having received payments from CareDx and Natera for consulting and working at an institution that received research payments from CareDx and Natera. Neither CareDx nor Natera were involved in the conceptualization of the study, data collection and analysis, manuscript preparation, and editing of the final manuscript.Funding StatementThe project described was partially supported by the National Institutes of Health (PJK), Grants UL1TR001442 and 1KL2TR001444. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Nicholas Wettersten and this work was supported (or supported in part) by Career Development Award Number IK2 CX002105 from the United States (U.S.) Department of Veterans Affairs Clinical Sciences R&D (CSRD) Service. The contents do not represent the view of the U.S. Department of Veterans Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for this study was provided by the UC San Diego Health Office of IRB Administration (IRB #805675).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://data.mendeley.com/datasets/d4f7g8hs5z/1ACRAcute cellular rejectionCAVCardiac allograft vasculopathyDCDDonation after circulatory deathdnDSAde novo donor-specific antibodyDSADonor-specific antibodyEMBEndomyocardial biopsyHLAHuman leukocyte antigenHTxHeart transplantationISHLTInternational Society for Heart and Lung TransplantationMFIMean fluorescence intensitypAMRPathologic antibody mediated rejectionPGDPrimary graft dysfunctionUCSDUniversity of California, San Diego Health